#None #Frost & Sullivan #Viva Biotech #AI Drug Discovery

Viva Biotech Achieves Frost & Sullivan's 2025 APAC Technology Innovation Leadership

Viva Biotech has recently been awarded the prestigious 2025 APAC Technology Innovation Leadership recognition in the integrated intelligent drug discovery industry by Frost & Sullivan. This accolade underlines the company’s significant accomplishments in enhancing efficiencies in preclinical research and development. Through its innovative AI-driven drug discovery platforms, Viva Biotech not only accelerates timelines and reduces costs but also amplifies therapeutic innovation across the global pharmaceutical R&D ecosystem.

Frost & Sullivan highlights that Viva Biotech excels in merging artificial intelligence with laboratory-driven validation, which reshapes the future of drug discovery. Their focus on fostering client partnerships while delivering scalable innovations has positioned them positively within a highly competitive landscape.

The evaluation process employed by Frost & Sullivan was rigorous, assessing companies on two critical dimensions: strategy effectiveness and execution. Viva Biotech showcased excellence in aligning advanced technologies with client needs both precisely and at scale. As articulated by Priyanka Jain, a senior research analyst with Frost & Sullivan, the company has successfully integrated multimodal artificial intelligence with extensive wet lab validation, creating one of the industry’s most adaptable discovery platforms. This platform supports a variety of modalities ranging from small molecules and antibodies to cutting-edge therapies, significantly shortening development timelines and curtailing costs for clients globally.

Viva Biotech’s long-term growth strategy is centered on digital innovation, collaboration with clients, and operational efficiency. The company has demonstrated exceptional agility in adapting to the ever-evolving pharmaceutical research landscape. By investing in AI-driven modeling, structure-based drug discovery, and seamless lab-in-the-loop systems, it has hastened decision-making processes, enabling both first-in-class and fast-follow programs for its worldwide clientele.

Innovation is at the core of Viva Biotech's mission. Its Artificial Intelligence-Driven Drug Discovery (AIDD) platform, which comprises proprietary modules such as V-Scepter, V-Orb, and V-Mantle, tackles long-standing challenges in drug design. This platform synthesizes predictive modeling, physics-based simulations, and generative AI, all integrated directly with wet lab experimentation to facilitate rapid validation and iterative improvement of drug candidates.

"We are deeply honored to receive this award from Frost & Sullivan," stated Dr. Derek Ren, CEO of Viva Biotech (Shanghai) Ltd. "This recognition affirms our vision of establishing a fully integrated platform that brings together AI-driven drug discovery and structure-based drug design. Our AI platform is making previously impossible breakthroughs possible. Moving forward, we are committed to accelerating the pace of AI-driven drug discovery and leading the charge into a new era of scientific innovation."

Moreover, Viva Biotech’s commitment to enhancing the client experience is evident in their flexible collaboration models and milestone-based agreements, which allow partners to retain full ownership of their intellectual property. This strategy not only delivers substantial value but also cultivates long-term trust in their relationships. Their integrated service capabilities are designed to mitigate project risks and empower clients to confidently explore emerging modalities with speed and scientific precision.

Frost & Sullivan commends Viva Biotech for establishing a benchmark in technological innovation, strategic execution, and client-centric growth. Their AI-first approach, bolstered by top-tier expertise in structural biology and preclinical experimentation, is shaping the landscape of integrated intelligent drug discovery, yielding measurable outcomes across various therapeutic domains.

Each year, the Technology Innovation Leadership recognition from Frost & Sullivan is awarded to a company that demonstrates exemplary strategy development and execution, resulting in tangible improvements in market presence, customer satisfaction, and competitive position. This honor acknowledges organizations that redefine their industries through transformative innovation and excellence in growth.

In summary, Viva Biotech exemplifies the potential for AI to revolutionize drug discovery, setting a high bar for innovation and customer-centric operations in the biopharmaceutical industry. As the company continues to drive advancements in this space, they reaffirm their commitment to delivering exceptional value to clients and reshaping the future of healthcare.